News
KRYS
260.95
+0.79%
2.04
Weekly Report: what happened at KRYS last week (0330-0403)?
Weekly Report · 2h ago
Krystal Biotech announces annual shareholder meeting notice, releases proxy statement
Reuters · 2d ago
XSMO, ESE, KRYS, PTGX: ETF Outflow Alert
NASDAQ · 4d ago
Weekly Report: what happened at KRYS last week (0323-0327)?
Weekly Report · 03/30 10:23
Krystal Biotech Initiated at Peer Perform by Wolfe Research
Dow Jones · 03/27 12:05
Wolfe Research Initiates Coverage On Krystal Biotech with Peer Perform Rating
Benzinga · 03/27 11:55
Krystal Biotech (KRYS) Valuation Check After Recent Pullback And Mixed Earnings Multiple Signals
Simply Wall St · 03/27 10:04
Krystal Biotech: Valuation Reflects Pipeline Optimism Amid Dosing and Efficacy Risks, Justifying a Hold Rating
TipRanks · 03/26 20:26
Krystal Biotech initiated with a Peer Perform at Wolfe Research
TipRanks · 03/26 20:23
Krystal Biotech price target raised to $325 from $318 at BofA
TipRanks · 03/24 11:35
Bank of America Securities Remains a Buy on Krystal Biotech (KRYS)
TipRanks · 03/24 10:17
KRYSTAL BIOTECH INC <KRYS.O>: BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $325 FROM $318
Reuters · 03/24 10:00
U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco
Reuters · 03/24 07:39
Palvella Therapeutics appoints Jennifer J. McDonough as SVP of Market Access and Patient Services
Reuters · 03/23 11:31
Weekly Report: what happened at KRYS last week (0316-0320)?
Weekly Report · 03/23 10:20
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
NASDAQ · 03/20 12:00
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
NASDAQ · 03/20 11:59
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
NASDAQ · 03/20 11:59
A Look At Krystal Biotech (KRYS) Valuation After Updated Vyjuvek Label And Pipeline Momentum
Simply Wall St · 03/19 23:20
Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB
Seeking Alpha · 03/19 17:18
More
Webull provides a variety of real-time KRYS stock news. You can receive the latest news about Krystal Biotech through multiple platforms. This information may help you make smarter investment decisions.
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.